Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine.

Literature DB >> 25552727

Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine.

Andrew Cox¹, Steven F Baker¹, Aitor Nogales¹, Luis Martínez-Sobrido², Stephen Dewhurst².

Abstract

The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pathogenicity that retains lethality at high doses and further demonstrate that we can enhance safety in vivo through mutations within NS1. This model may permit preliminary safety analysis of improved LAIVs.

Entities: Gene Species

Mesh：

Substances：

Year: 2014 PMID： 25552727 PMCID： PMC4337518 DOI： 10.1128/JVI.02636-14

Source DB: PubMed Journal: J Virol ISSN： 0022-538X Impact factor: 5.103

29 in total

1. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination.

Authors: Christopher S Ambrose; Xionghua Wu; Robert B Belshe
Journal: Pediatr Infect Dis J Date: 2010-09 Impact factor: 2.129

2. Genetic analysis of influenza virus NS1 gene: a temperature-sensitive mutant shows defective formation of virus particles.

Authors: Urtzi Garaigorta; Ana M Falcón; Juan Ortín
Journal: J Virol Date: 2005-12 Impact factor: 5.103

3. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.

Authors: Robert B Belshe; Christopher S Ambrose; Tingting Yi
Journal: Vaccine Date: 2008-09-12 Impact factor: 3.641

4. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.

Authors: Stan L Block; Ram Yogev; Frederick G Hayden; Christopher S Ambrose; Wen Zeng; Robert E Walker
Journal: Vaccine Date: 2008-07-26 Impact factor: 3.641

5. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines.

Authors: M H Snyder; R F Betts; D DeBorde; E L Tierney; M L Clements; D Herrington; S D Sears; R Dolin; H F Maassab; B R Murphy
Journal: J Virol Date: 1988-02 Impact factor: 5.103

6. Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2).

Authors: N J Cox; F Kitame; A P Kendal; H F Maassab; C Naeve
Journal: Virology Date: 1988-12 Impact factor: 3.616

7. Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene.

Authors: Daniel Grimm; Peter Staeheli; Martin Hufbauer; Iris Koerner; Luis Martínez-Sobrido; Alicia Solórzano; Adolfo García-Sastre; Otto Haller; Georg Kochs
Journal: Proc Natl Acad Sci U S A Date: 2007-04-10 Impact factor: 11.205

8. Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets.

Authors: Grace L Chen; Elaine W Lamirande; Hong Jin; George Kemble; Kanta Subbarao
Journal: Virology Date: 2009-12-24 Impact factor: 3.616

9. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Authors: Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao
Journal: PLoS Med Date: 2006-09 Impact factor: 11.069

10. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age.

Authors: Robert B Belshe; Seth L Toback; Tingting Yi; Christopher S Ambrose
Journal: Influenza Other Respir Viruses Date: 2010-05-01 Impact factor: 4.380

24 in total

1. Interplay of PA-X and NS1 Proteins in Replication and Pathogenesis of a Temperature-Sensitive 2009 Pandemic H1N1 Influenza A Virus.

Authors: Aitor Nogales; Laura Rodriguez; Marta L DeDiego; David J Topham; Luis Martínez-Sobrido
Journal: J Virol Date: 2017-08-10 Impact factor: 5.103

2. Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA).

Authors: Steven F Baker; Aitor Nogales; Felix W Santiago; David J Topham; Luis Martínez-Sobrido
Journal: Vaccine Date: 2015-06-01 Impact factor: 3.641

10. A Single Mutation at PB1 Residue 319 Dramatically Increases the Safety of PR8 Live Attenuated Influenza Vaccine in a Murine Model without Compromising Vaccine Efficacy.

Authors: Andrew Cox; Stephen Dewhurst
Journal: J Virol Date: 2015-12-16 Impact factor: 5.103

Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine.

1. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination.

2. Genetic analysis of influenza virus NS1 gene: a temperature-sensitive mutant shows defective formation of virus particles.

3. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.

4. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.

5. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines.

6. Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2).

7. Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene.

8. Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets.

9. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

10. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age.

1. Interplay of PA-X and NS1 Proteins in Replication and Pathogenesis of a Temperature-Sensitive 2009 Pandemic H1N1 Influenza A Virus.

2. Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA).

Review 3. Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

4. Temperature-Sensitive Live-Attenuated Canine Influenza Virus H3N8 Vaccine.

5. Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.

6. Influenza A Virus Studies in a Mouse Model of Infection.

7. A Novel Fluorescent and Bioluminescent Bireporter Influenza A Virus To Evaluate Viral Infections.

Review 8. Development and applications of single-cycle infectious influenza A virus (sciIAV).

9. Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines.

10. A Single Mutation at PB1 Residue 319 Dramatically Increases the Safety of PR8 Live Attenuated Influenza Vaccine in a Murine Model without Compromising Vaccine Efficacy.